Evidence map›Paper›PMID 40604035›Full record

ArticleScientific reports2025

Donor and recipient genetic variants in drug metabolizing enzymes and transporters affect early tacrolimus pharmacokinetics after liver transplantation.

Alexandra D Ladd, Isabella Angeli-Pahim, Duncan Lewis, Curtis Warren, Satyavardhan Nittu, Jatinder Lamba, Sergio Duarte, Ali Zarrinpar

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Scientific reports, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 3 papers.

0numbers the graph read from it
0cells of the map it votes in
3citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

3 citing papers in PubMed.

  1. Article
  2. Article
  3. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Alexandra D Ladd *Department of Surgery, College of Medicine, University of Florida, PO Box 100118, Gainesville, FL, 32608, USA.
Isabella Angeli-Pahim *Department of Surgery, College of Medicine, University of Florida, PO Box 100118, Gainesville, FL, 32608, USA.
Duncan LewisDepartment of Surgery, College of Medicine, University of Florida, PO Box 100118, Gainesville, FL, 32608, USA.
Curtis WarrenDepartment of Surgery, College of Medicine, University of Florida, PO Box 100118, Gainesville, FL, 32608, USA.
Satyavardhan NittuDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Jatinder LambaDepartment of Pharmacotherapy and Translational Research, College of Pharmacy, University of Florida, Gainesville, FL, USA.
Sergio DuarteDepartment of Surgery, College of Medicine, University of Florida, PO Box 100118, Gainesville, FL, 32608, USA.
Ali ZarrinparDepartment of Surgery, College of Medicine, University of Florida, PO Box 100118, Gainesville, FL, 32608, USA. ali.zarrinpar@surgery.ufl.edu.

Funding

Training Program for Applied Research and Development in Genomic MedicineT32HG008958 · NHGRI · UNIVERSITY OF FLORIDA · PI Larisa Humma Cavallari, Stephen E. Kimmel · 2018 to 2026
$3.8M
Optimizing Immunosuppression Drug Dosing via Phenotypic Precision MedicineR21DK116140 · NIDDK · UNIVERSITY OF FLORIDA · PI ZARRINPAR, ALI · 2018 to 2019
$364k
NHGRI NIH HHS T32 HG008958NHGRI NIH HHS T32HG008958NIDDK NIH HHS R21 DK116140NIDDK NIH HHS R21DK116140
6 · The paper itself

Abstract

This study examines the influence of single nucleotide polymorphisms in drug metabolizing enzymes CYP3A4, CYP3A5, and UGT1A4, and the transporter ABCB1 on tacrolimus dose requirements and blood trough level variability in the period immediately after liver transplantation. We analyzed genotypes for these genes in 61 adult liver transplant recipients who received tacrolimus and their respective donors. Significant findings include increased average daily deviation (ADD) from the therapeutic range in patients with: donor CYP3A4*22 GG (1.68 [1.01, 2.29] versus 0.68 [0.42, 1.46] ng/mL/day, p = 0.016), recipient ABCB1 rs2032582 CT/TT (2.07 [1.68, 2.39] versus 1.37 [0.76, 1.95] ng/mL/day , p = 0.013), and donor UGT1A4*3 TT (1.69 [1.02, 2.42] versus 1.33 [0.54, 1.79] ng/mL/day , p = 0.043). Additionally, higher tacrolimus concentration/weight-adjusted dose ratios [C

Indexed as

Cytochrome P-450 CYP3AImmunosuppressive AgentsLiver TransplantationPolymorphism, Single NucleotideTacrolimusAdultAgedATP Binding Cassette Transporter, Subfamily BFemaleGenotypeGlucuronosyltransferaseHumansMaleMiddle AgedTissue DonorsTransplant RecipientsABCB1 protein, humanATP Binding Cassette Transporter, Subfamily BCYP3A4 protein, humanCYP3A5 protein, humanCytochrome P-450 CYP3AGlucuronosyltransferaseImmunosuppressive AgentsTacrolimusABCB1CYP3A4CYP3A5ImmunosuppressionLiver transplantationPharmacogeneticsPharmacokineticsPost-transplant dosingSingle nucleotide polymorphismTacrolimusUGT1A4

Identifiers

PMID40604035
PMCPMC12223032

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.